What milrinone infusion rate (mL per hour) is required to achieve a dose of 0.25 µg per kilogram per hour for a patient weighing 108.9 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Milrinone Infusion Rate Calculation for 0.25 mcg/kg/hr

For a 108.9 kg patient receiving milrinone at 0.25 mcg/kg/hr, the required infusion rate is 1.63 mL/hr using the standard 200 mcg/mL concentration.

Step-by-Step Calculation

1. Calculate Total Hourly Dose Required

  • Patient weight: 108.9 kg
  • Desired dose: 0.25 mcg/kg/hr
  • Total dose = 0.25 mcg/kg/hr × 108.9 kg = 27.225 mcg/hr 1

2. Convert to Infusion Rate Using Standard Concentration

  • Standard milrinone concentration: 200 mcg/mL 1
  • Infusion rate = 27.225 mcg/hr ÷ 200 mcg/mL = 0.136 mL/hr

However, this calculation reveals a critical clinical issue: The dose of 0.25 mcg/kg/hr appears to be an error—milrinone maintenance dosing is prescribed in mcg/kg/min, not per hour.

Corrected Calculation Assuming Standard Dosing

If the Intended Dose is 0.25 mcg/kg/min (Standard Low-Dose Maintenance):

  • Total dose = 0.25 mcg/kg/min × 108.9 kg = 27.225 mcg/min
  • Convert to hourly: 27.225 mcg/min × 60 min/hr = 1,633.5 mcg/hr
  • Infusion rate = 1,633.5 mcg/hr ÷ 200 mcg/mL = 8.17 mL/hr 1

Standard Milrinone Dosing Reference

The FDA-approved maintenance infusion range is 0.375 to 0.75 mcg/kg/min, with a minimum of 0.375 mcg/kg/min for therapeutic effect 1. A dose of 0.25 mcg/kg/min was studied and found to be ineffective for maintenance therapy 2.

Preparation Protocol

Standard Concentration Preparation

  • Add 20 mL of milrinone 1 mg/mL to 80 mL of compatible diluent (0.9% NaCl, 0.45% NaCl, or D5W) 1
  • Final concentration: 200 mcg/mL in 100 mL total volume 1

Loading Dose Consideration

  • Standard loading dose: 50 mcg/kg over 10 minutes 1
  • For this patient: 50 mcg/kg × 108.9 kg = 5,445 mcg = 5.4 mL of 1 mg/mL solution 1
  • Omit the loading dose if systolic BP <100 mmHg to prevent hypotension 3, 4
  • Consider dividing the bolus into five equal aliquots over 10 minutes each if blood pressure stability is a concern 3

Critical Monitoring Requirements

Hemodynamic Monitoring

  • Target MAP ≥65 mmHg during milrinone administration 3
  • Monitor for systemic hypotension, the most common adverse effect 3, 4
  • Continuous ECG telemetry for arrhythmia detection 3

Management of Hypotension

  • If hypotension occurs, reverse with titrated boluses of isotonic crystalloid or colloid 3
  • Consider initiating norepinephrine 0.2-1.0 mcg/kg/min or vasopressin to overcome hypotension-related toxicity 3, 4
  • Discontinue milrinone immediately at first sign of arrhythmia or excessive vasodilation 3

Renal Dose Adjustment

This patient requires assessment of creatinine clearance before dosing. The FDA label provides specific dose reductions for renal impairment 1:

Creatinine Clearance Adjusted Infusion Rate
50 mL/min 0.43 mcg/kg/min
40 mL/min 0.38 mcg/kg/min
30 mL/min 0.33 mcg/kg/min
20 mL/min 0.28 mcg/kg/min
10 mL/min 0.23 mcg/kg/min
5 mL/min 0.20 mcg/kg/min

Clinical Context Warnings

Contraindications to Long-Term Use

  • Milrinone may be harmful with long-term use outside palliative care or bridge to transplant therapy 3, 4
  • Inotropic agents should be used with caution, starting from low doses with close monitoring 5

Advantages Over Dobutamine

  • Milrinone is preferred over dobutamine in patients on beta-blocker therapy because its mechanism of action is distal to beta-adrenergic receptors 5, 3, 4
  • Produces balanced inotropic and vasodilatory effects, reducing both preload and afterload 3, 4

Duration of Action

  • Elimination half-life ranges from 1-10 hours depending on organ function 3
  • Observe in hospital for at least 48 hours after discontinuation to assess adequacy of oral-based strategies 3
  • Gradual tapering is essential to prevent acute decompensation 3

References

Guideline

Milrinone Side Effects and Clinical Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Milrinone Dosing for Right Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What emergency condition could cause a dog with prolonged heavy panting, weakness, vomiting, extreme thirst, seizures and rapid death, and how should it be treated?
In a 21-year-old female runner who developed leg pain and progressively spreading bruising, what urgent evaluation and management are indicated?
What is the appropriate work‑up and management for a 28‑year‑old with chronic left‑sided retro‑auricular pain, intermittent palpable lump behind the ear, mild external auditory canal erythema, pain on otoscope insertion, and a history of bilateral infant grommets?
In a 4-month-old exclusively breastfed infant whose weight has fallen from the 50th to the 10th percentile, what advice should be given to the parents to prevent further weight loss?
Can you interpret the X‑ray findings for a 71‑year‑old female who fell, injuring her left elbow and lumbar spine?
Can I give ibuprofen to a 3‑year‑old one hour after giving acetaminophen (Tylenol) for fever?
What gram sizes are available for clobetasol (0.05% topical corticosteroid) formulations?
How should a post‑viral neck rash be evaluated and managed?
Is daily oral Truvada (tenofovir disoproxil fumarate + emtricitabine) safe for HIV pre‑exposure prophylaxis (PrEP) while breastfeeding, and should Apretude (cabotegravir) be avoided during lactation?
What is the step‑by‑step management of a patient presenting to the office requesting a medical abortion?
What treatment would you recommend to improve glycemic control in a 62-year-old patient with poorly controlled type 2 diabetes mellitus and no major comorbidities?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.